Articles from 20/20 Biolabs Inc.

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed 
By 20/20 Biolabs Inc. · Via GlobeNewswire · May 22, 2026
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026
By 20/20 Biolabs Inc. · Via GlobeNewswire · May 20, 2026
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results
By 20/20 Biolabs Inc. · Via GlobeNewswire · May 12, 2026
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
Joint Release Expands 20/20 BioLabs’ Testing Solutions Across Evexia’s Network of ~40,000 Functional and Integrative Medicine Practitioners
By 20/20 Biolabs Inc. · Via GlobeNewswire · April 7, 2026
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
Full Year 2025 Revenue of $2.0 Million, up 17% from 2024
By 20/20 Biolabs Inc. · Via GlobeNewswire · March 31, 2026
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools 
By 20/20 Biolabs Inc. · Via GlobeNewswire · March 27, 2026
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
Inflammatory Biomarker Tracking Predicted to Enhance 
By 20/20 Biolabs Inc. · Via GlobeNewswire · March 24, 2026
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage Cancers
By 20/20 Biolabs Inc. · Via GlobeNewswire · March 12, 2026
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights
By 20/20 Biolabs Inc. · Via GlobeNewswire · February 25, 2026
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
By 20/20 Biolabs Inc. · Via GlobeNewswire · February 20, 2026
20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth
Company Ready to Scale Growth through OneTest™ AI-Powered Blood Tests for Cancer and Longevity
By 20/20 Biolabs Inc. · Via GlobeNewswire · February 19, 2026